Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR)

Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR)

Current guidelines favor dual anti-platelet therapy with ticagrelor 90 mg BID (T90BID) over clopidogrel 75 mg QD (C75QD) in addition to aspirin for acute coronary syndrome. However, an increased risk of ticagrelor-related adverse events prompted the evaluation of low-dose regimens. This study (NCT03...

Full description

Bibliographic Details
Main Authors: Jing Shi, Meijiao He, Wennan Wang, Guangzhong Liu, Haiyu Zhang, Danghui Sun, Jianqiang Li, Hongyuan Mu, Minglu Xu, Chenyang Zhao, Jiayu Wang, Chongyang Zhang, Hai Cang, Shiqi Zhao, Zhiren Zhang, Yue Li
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Platelets
Subjects:
bleeding
clopidogrel
inhibition of platelet aggregation
low-dose ticagrelor
Online Access:http://dx.doi.org/10.1080/09537104.2020.1732328

Internet

http://dx.doi.org/10.1080/09537104.2020.1732328

Similar Items